Transgene SA (EPA:TNG)
0.8810
-0.0010 (-0.11%)
Sep 11, 2026, 5:35 PM CET
Transgene Market Cap
Transgene has a market cap or net worth of €241.29 million as of September 11, 2026. Its market cap has increased by 62.02% in one year.
Market Cap
241.29M
Enterprise Value
131.49M
Revenue
7.21M
Ranking
n/a
PE Ratio
n/a
Stock Price
€0.88
ChartMarket Cap Chart
Since March 30, 1998, Transgene's market cap has increased from 151.86M to 241.29M, an increase of 58.89%. That is a compound annual growth rate of 1.64%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 11, 2026 | 241.29M | -8.21% |
| Dec 31, 2025 | 262.87M | 192.89% |
| Dec 31, 2024 | 89.75M | -34.86% |
| Dec 29, 2023 | 137.78M | -16.38% |
| Dec 30, 2022 | 164.76M | -33.52% |
| Dec 31, 2021 | 247.84M | 79.73% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| MedinCell | 790.77M |
| DBV Technologies | 697.77M |
| Genfit | 615.30M |
| Valneva SE | 549.60M |
| Valerio Therapeutics Société anonyme | 359.60M |
| Cellectis | 199.19M |
| Innate Pharma | 155.72M |
| Sensorion | 122.76M |